Latest News and Press Releases

AUTO3 continues to show a differentiated product profile supporting outpatient administration Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm ET / 9:00 pm GMT LONDON, Dec....

-  AUTO3 shows promise of a highly differentiated product profile Conference call and webcast to be held Friday, September 18, 2020 at 8:00 am EDT / 1:00 pm BST LONDON, Sept. 18, 2020 (GLOBE...

Pivotal AUTO1 study in adult ALL patients enrolling -  AUTO1 continued favorable safety profile and high level of clinical activity, pivotal Phase 1b/2 AUTO1-AL1 program in adult ALL initiated and...

LONDON, June 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...

– Data continue to show encouraging clinical activity alongside tolerable safety to deliver a potentially highly differentiated product profile – Conference call and webcast to be held Monday, June...

– Data builds on positive data presented at American Society of Hematology in December 2019 and EHA-EMBT 2nd European CAR T Cell Meeting in February 2020 – Conference Call and Webcast to be held...

- Virtual oral presentation will include additional patient data as well as longer term data on previously treated patients - Conference Call and Webcast to Be Held Monday, June 1, 2020 at 8:30...

- Initial data show encouraging clinical activity with manageable safety profile - No neurotoxicity observed to date in patients treated with AUTO3 + pembrolizumab Data presented at EHA-EBMT 2nd...

LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces that...

AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome   Data presented at 61st American Society of Hematology Annual Meeting form...